Abstract
..
Main
..
RCT vs. Obs.
..
Feedback
Home
c19early.org COVID-19 treatment researchQuercetinQuercetin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
 
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Quercetin reduces COVID-19 risk: real-time meta analysis of 12 studies

@CovidAnalysis, December 2024, Version 22V22
Post
Share
PDF
Studies
Feedback
https://c19early.org/qmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Di Pierro (RCT) 86% 0.14 [0.01-2.72] death 0/76 3/76 Improvement, RR [CI] Treatment Control Di Pierro (RCT) 94% 0.06 [0.01-0.45] ICU 0/76 8/76 Di Pierro (RCT) 68% 0.32 [0.14-0.70] hosp. 7/76 22/76 Khan (RCT) 33% 0.67 [0.37-1.19] no recov. 10/25 15/25 CT​1​ Khan (RCT) 39% 0.61 [0.43-0.87] no recov. 25 (n) 25 (n) CT​1​ Khan (RCT) 50% 0.50 [0.30-0.84] viral+ 10/25 20/25 CT​1​ Di Pierro (RCT) 67% 0.33 [0.01-7.99] death 0/50 1/50 Di Pierro (RCT) 67% 0.33 [0.01-7.99] ICU 0/50 1/50 Di Pierro (RCT) 67% 0.33 [0.01-7.99] hosp. 0/50 1/50 Di Pierro (RCT) 37% 0.63 [0.46-0.88] no recov. 24/50 38/50 Di Pierro (RCT) 58% 0.42 [0.27-0.65] viral+ 16/50 38/50 Di Pierro (RCT) -50% 1.50 [0.26-8.60] viral+ 3/50 2/50 Di Pierro (RCT) 67% 0.33 [0.01-7.99] viral+ 0/50 1/50 Din Ujjan (RCT) 29% 0.71 [0.50-1.03] no recov. 15/25 21/25 CT​1​ Din Ujjan (RCT) 71% 0.29 [0.14-0.59] no recov. 6/25 21/25 CT​1​ Din Ujjan (RCT) 77% 0.23 [0.07-0.71] no recov. 3/25 13/25 CT​1​ Din Ujjan (RCT) 86% 0.14 [0.01-2.63] no recov. 0/25 3/25 CT​1​ Din Ujjan (RCT) 91% 0.09 [0.01-1.56] viral+ 0/25 5/25 CT​1​ Din Ujjan (RCT) 74% 0.26 [0.12-0.59] viral+ 5/25 19/25 CT​1​ Onal (RCT) -29% 1.29 [0.16-10.5] death 1/49 6/380 CT​1​ Onal (RCT) 94% 0.06 [0.00-31.8] ICU 0/49 14/380 CT​1​ Onal (RCT) 78% 0.22 [0.03-1.58] no disch. 1/49 35/380 CT​1​ Zupanets (RCT) 29% 0.71 [0.32-1.58] no recov. 9/99 13/101 Zupanets (RCT) 18% 0.82 [0.68-0.98] recov. time 99 (n) 101 (n) Shohan (RCT) 86% 0.14 [0.01-2.65] death 0/30 3/30 Shohan (RCT) 40% 0.60 [0.16-2.29] ICU 3/30 5/30 Shohan (RCT) 32% 0.68 [0.47-0.98] recov. time 30 (n) 30 (n) Gérain (RCT) 67% 0.33 [0.01-7.70] death 0/25 1/24 CT​1​ Gérain (RCT) 91% 0.09 [0.01-0.71] death/ICU 0/25 5/24 CT​1​ Gérain (RCT) 89% 0.11 [0.01-1.92] ventilation 0/25 4/24 CT​1​ Gérain (RCT) 89% 0.11 [0.01-1.92] ICU 0/25 4/24 CT​1​ Gérain (RCT) 73% 0.27 [0.06-1.19] no disch. 2/25 7/24 CT​1​ Gérain (RCT) 59% 0.41 [0.19-0.89] no disch. 6/25 14/24 CT​1​ Gérain (RCT) 38% 0.62 [0.44-0.88] hosp. time 25 (n) 24 (n) CT​1​ Gérain (RCT) 50% 0.50 [0.26-0.97] no recov. 22 (n) 24 (n) CT​1​ Tylishchak (RCT) 40% 0.60 [0.16-2.29] no recov. 3/30 5/30 Tylishchak (RCT) 15% 0.85 [0.81-0.89] hosp. time 30 (n) 30 (n) Arslan (RCT) 92% 0.08 [0.01-0.79] cases 1/71 9/42 CT​1​ Margolin 94% 0.06 [0.00-0.93] cases 0/53 9/60 CT​1​ Margolin 81% 0.19 [0.04-0.80] cases 2/53 12/60 CT​1​ Rondanelli (DB RCT) 93% 0.07 [0.01-0.91] symp. case 1/60 4/60 Quercetin COVID-19 outcomes c19early.org December 2024 ​1​ CT: study uses combined treatment Favors quercetin Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0